Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia - NCT00313586-54601(Clinical Trial 307845)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
La Crosse |
|
State:
|
|
WI |
| Zip Code: |
|
54601 |
| Conditions: |
|
Leukemia - Myelodysplastic Syndromes |
| Purpose: |
|
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Giving azacitidine together with MS-275 may kill more cancer cells.
PURPOSE: This randomized phase II trial is studying azacitidine and MS-275 to see how well
they work compared to azacitidine alone in treating patients with myelodysplastic syndromes,
chronic myelomonocytic leukemia, or acute myeloid leukemia.
|
| Study summary: |
|
OBJECTIVES:
Primary
- Compare the overall response rate (complete, partial, and hematologic improvement-major
by International Working Group [IWG] criteria) in patients with treatment-induced or
non-treatment-induced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia
(dysplastic), or acute myeloid leukemia with multilineage dysplasia treated with
azacitidine with vs without MS-275.
- Compare the major response rate (complete and partial responses by IWG criteria) in
patients treated with these regimens.
Secondary
- Evaluate the toxicity of azacitidine and MS-275 in these patients.
- Identify changes in gene promoter methylation and gene expression that may be
associated with response to azacitidine and MS-275.
- Identify other molecular mechanisms (such as DNA damage) that may be associated with
response to azacitidine and MS-275.
OUTLINE: This is a randomized, multicenter study. Patients are first stratified according to
treatment-related disease (yes vs no), followed by a second stratification according to
disease (myelodysplastic syndromes [MDS] high/intermediate-2 vs MDS low/intermediate-1 vs
chronic myelomonocytic leukemia vs acute myeloid leukemia with multilineage dysplasia).
Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive azacitidine subcutaneously once daily on days 1-10.
- Arm II: Patients receive azacitidine as in arm I and oral MS-275 on days 3 and 10.
Treatment in both arms repeats every 28 days for at least 6 and up to 24 courses in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
PROJECTED ACCRUAL: A total of 196 patients will be accrued for this study. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Bone marrow aspirate and/or biopsy-confirmed diagnosis of 1 of the following:
- Myelodysplastic syndromes (MDS)
- Any International Prognostic Score (IPSS) eligible
- Patients with low or intermediate-1 IPSS must have platelet count <
50,000/mm³ and/or absolute neutrophil count < 500/mm³
- Blast count < 20%
- Chronic myelomonocytic leukemia (dysplastic subtype)
- WBC < 12,000/mm³ (measured twice within the past 4 weeks, 2 weeks apart)
- Acute myeloid leukemia with multilineage dysplasia (AML-TLD)
- Formerly diagnosed refractory anemia with excess blasts in transformation
by FAB criteria allowed
- AML-TLD by WHO criteria allowed in patients with no history of antecedent
hematologic disorder
- WBC ≤ 30,000/mm³ (measured twice within the past 4 weeks, 2 weeks apart)
- WBC that has doubled over 4 weeks AND > 20,000/mm³ is not eligible
- Evidence of ≥ 20% blasts on review of the bone marrow aspirate and/or
biopsy
- SWOG patients must be enrolled in research study trial SWOG-9007
- Therapy-induced MDS, AML-TLD, or chronic myelomonocytic leukemia (dysplastic subtype)
allowed
- No clinical evidence of CNS or pulmonary leukostasis or disseminated intravascular
coagulation
- No clinical evidence of CNS leukemia
PATIENT CHARACTERISTICS:
- See Disease Characteristics
- ECOG performance status 0-2
- Life expectancy ≥ 6 months
- Creatinine < 2.0 mg/dL
- Bilirubin normal (unless due to intramedullary or extramedullary hemolysis, or
Gilbert's syndrome)
- AST and ALT ≤ 2.5 times upper limit of normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infections
- No advanced malignant hepatic tumors
- No other serious or uncontrolled medical conditions
- No known hypersensitivity to azacitidine or mannitol
PRIOR CONCURRENT THERAPY:
- Recovered from prior therapy
- No prior azacitidine, decitabine or MS-275
- No prior induction chemotherapy for AML or stem cell transplantation
- No hematopoietic growth factors within 3 weeks prior to study entry
- No other concurrent investigational or commercial agents or therapies for the
malignancy
- No concurrent valproic acid, epoetin alfa, or darbepoetin alfa
- No filgrastim (G-CSF) or pegfilgrastim during days 1-10 of each treatment course |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 17, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|